- Home
- AMTB vs PHVS Comparison
AMTB vs PHVS Comparison
Compare AMTB & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMTB
- PHVS
- Stock Information
- Founded
- AMTB 1979
- PHVS 2015
- Country
- AMTB United States
- PHVS Switzerland
- Employees
- AMTB N/A
- PHVS N/A
- Industry
- AMTB Major Banks
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- AMTB Finance
- PHVS Health Care
- Exchange
- AMTB Nasdaq
- PHVS Nasdaq
- Market Cap
- AMTB 753.3M
- PHVS 980.3M
- IPO Year
- AMTB N/A
- PHVS 2021
- Fundamental
- Price
- AMTB $19.83
- PHVS $18.60
- Analyst Decision
- AMTB Hold
- PHVS Buy
- Analyst Count
- AMTB 5
- PHVS 6
- Target Price
- AMTB $24.33
- PHVS $37.17
- AVG Volume (30 Days)
- AMTB 213.8K
- PHVS 35.9K
- Earning Date
- AMTB 07-23-2025
- PHVS 08-13-2025
- Dividend Yield
- AMTB 1.83%
- PHVS N/A
- EPS Growth
- AMTB N/A
- PHVS N/A
- EPS
- AMTB N/A
- PHVS N/A
- Revenue
- AMTB $280,716,000.00
- PHVS N/A
- Revenue This Year
- AMTB $57.57
- PHVS N/A
- Revenue Next Year
- AMTB $8.91
- PHVS N/A
- P/E Ratio
- AMTB N/A
- PHVS N/A
- Revenue Growth
- AMTB N/A
- PHVS N/A
- 52 Week Low
- AMTB $16.21
- PHVS $11.51
- 52 Week High
- AMTB $27.00
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- AMTB 71.41
- PHVS 60.00
- Support Level
- AMTB $17.43
- PHVS $16.72
- Resistance Level
- AMTB $17.95
- PHVS $17.53
- Average True Range (ATR)
- AMTB 0.44
- PHVS 0.93
- MACD
- AMTB 0.28
- PHVS 0.07
- Stochastic Oscillator
- AMTB 95.15
- PHVS 92.86
About AMTB Amerant Bancorp Inc.
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.